The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
ZYME · Healthcare · No moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
| Measure | TXMD | ZYME | EBS | MRMD |
|---|---|---|---|---|
| Moat Score (0–100) | 36 (highest) | 36 (highest) | 36 (highest) | 36 (highest) |
| Methodology version | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 |
| Business trend | 48 | 60 (highest) | 15 | 54 |
| Pricing power | 80 (highest) | — | 68 | 66 |
| Returns on capital | 0 | 6 | 11 | 16 (highest) |
| Balance-sheet safety | 28 | 55 (highest) | 29 | 0 |
| Capital allocation | 24 | 24 | 57 (highest) | 44 |
| No price data | No price data | No price data | No price data | |
| Market cap | $23.8M | $1.7B | $378M | $26.2M |
| Moat tier | No moat | No moat | No moat | No moat |
| Filing date | FY2025 | FY2025 | FY2025 | FY2025 |